Release Date: July 17, 2026
Valid for Credit through: July 16, 2027
Program Overview:
This CME/CE program will examine the evolving role of high-efficacy anti-CD40 therapeutics in relapsing multiple sclerosis (RMS), with a focus on how emerging treatments may address both acute and chronic neuroinflammation. Expert faculty, Dr. Fred Lublin, will first review evolving concepts in MS pathophysiology, including the role of CNS-compartmentalized inflammation, microglial activation, meningeal lymphoid follicles, and progression independent of relapse activity. Dr. Lublin will then explore the CD40/CD40L pathway, elucidating its role in innate and adaptive immune activation for patients with MS. To conclude, ongoing clinical trial data in RMS and non-relapsing secondary progressive MS, including IV and subcutaneous administration strategies, will be discussed and contextualized for current clinical implications.
Target Audience
MS specialists, other neurologists, and other healthcare professionals involved in the management of patients with multiple sclerosis
Learning Objectives:
- Review strategies to assess individualized patient characteristics and disease prognosis to determine the role of CD40 in treatment planning
- Develop treatment plans to delay disability and progression in patients with RMS
Course Faculty
Fred D. Lublin, MD
Saunders Family Professor of Neurology Director
Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, NY
Provided by:
